ResMed (RMD) DIvidends Date & History

Key Takeaways

• ResMed offers a modest forward dividend yield of 1.09%, with a quarterly payment of $0.60 per share.
• The company has increased its dividend for 13 consecutive years, averaging 6.33% annual growth over the past five years.
• Payout ratio stands at a low 23%, indicating strong sustainability backed by robust earnings and free cash flow (FCF).
• Dividends consume only about 19% of free cash flow, providing ample room for continued growth.
• Compared to healthcare equipment peers, RMD's yield is average to low, prioritizing reinvestment for expansion.

Dividend Overview

ResMed (RMD), a leader in sleep apnea and respiratory care devices, maintains a modest quarterly dividend policy. The company currently pays $0.60 per share quarterly, equating to an annualized dividend of $2.40 and a forward yield of 1.09% as of recent data. The most recent ex-dividend date was February 12, 2026, with payment on March 19, 2026. This positions RMD as a dividend growth stock rather than a high-yield play, appealing to investors seeking reliable, gradually increasing income alongside capital appreciation in the medical devices sector.

Dividend History and Growth

ResMed has demonstrated consistent dividend growth, raising payouts for 13 consecutive years. Historical data shows steady quarterly increases, from $0.44 in early 2023 to $0.60 recently, reflecting a compound annual growth rate of approximately 7.7% over five years. No cuts have occurred in over a decade, underscoring the company's commitment to shareholders amid expanding operations in digital health and sleep therapy markets. This track record aligns with a strategy of balancing reinvestment in innovation with progressive returns.

Dividend Sustainability and Payout Ratio

ResMed's dividend sustainability is robust, supported by a trailing payout ratio of 22.35%—well below 50%, signaling ample earnings coverage. Earnings per share comfortably exceed dividend requirements, while free cash flow reached $1.3 billion in fiscal 2024, covering dividends multiple times over and paying out just 19% of FCF last year. Low debt levels and strong operating cash flow of $340 million in Q2 fiscal 2026 further bolster confidence in ongoing payments and potential future hikes. Financial stability in a growing healthcare niche enhances long-term viability.

Dividend Compared to Industry Peers

In the healthcare equipment sector, ResMed's 1.09% yield is modest compared to peers. For instance, MDT (Medtronic) offers around 3.3%, while ABT (Abbott Laboratories) yields about 1.9%. SYK (Stryker) has a similar low yield near 1%, and many like Intuitive Surgical (ISRG) pay none, focusing on growth. ResMed's lower payout ratio (22%) versus industry medians gives it more flexibility than higher-yielding rivals, positioning it as a conservative growth-oriented dividend payer.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your research.

Is This Stock Attractive for Dividend Investors?

ResMed (RMD) suits dividend growth investors who prioritize steady increases over high current yields. Its 13-year raise streak and low 23% payout ratio appeal to those seeking reliable income growth in a defensive healthcare sector, where demand for sleep and respiratory solutions remains resilient. Conservative long-term holders may value the strong FCF coverage and balance sheet, offering protection during economic cycles. However, income-focused investors chasing yields above 3% might look elsewhere, as RMD's 1.09% yield lags peers like Medtronic. Total return potential from appreciation could complement the modest dividend for patient portfolios. Balanced analysis shows appeal for growth-oriented dividend strategies rather than pure yield plays.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations